# Effectiveness of transcutaneous electrical acupoint stimulation for postoperative nausea, vomiting and pain in cancer patients: a systematic review and meta-analysis of randomized controlled trials

**Authors:** Jie Chu, Jiangxue You, Ruiqi Li, Zhe Wu, Chang Liu, Chao Tian

PMC · DOI: 10.3389/fmed.2026.1772210 · Frontiers in Medicine · 2026-02-13

## TL;DR

This study finds that transcutaneous electrical acupoint stimulation (TEAS) helps reduce postoperative pain and nausea in cancer patients, suggesting it could be a useful treatment.

## Contribution

The study provides a systematic review and meta-analysis of TEAS effectiveness for postoperative pain and nausea in cancer surgery patients.

## Key findings

- TEAS significantly reduced postoperative pain scores in cancer patients.
- TEAS decreased the incidence of postoperative nausea and vomiting.
- Further large-scale studies are needed to confirm long-term efficacy and standardize TEAS protocols.

## Abstract

To evaluate the effectiveness of transcutaneous electrical acupoint stimulation (TEAS) in relieving postoperative pain and reducing the incidence of postoperative nausea and vomiting (PONV) in patients undergoing cancer surgery.

A systematic search was conducted in PubMed, Web of Science, Embase, the Cochrane Library, CNKI, and Wanfang databases to identify randomized controlled trials (RCTs) published between January 2015 and May 2025. Postoperative pain scores at different time points, assessed using the visual analog scale (VAS) or numerical rating scale (NRS), as well as the incidence of PONV, postoperative nausea (PON), and postoperative vomiting (POV), were extracted. Subgroup analyses were performed according to the timing of TEAS intervention and pain assessment methods. The risk of bias was evaluated using the Cochrane Risk of Bias (RoB) tool, and the meta-analysis was conducted using RevMan 5.4 software.

A total of 16 randomized controlled trials involving 2,017 postoperative cancer patients were included (1,125 in the TEAS group and 892 in the control group). Meta-analysis of 13 studies showed that TEAS significantly reduced postoperative pain scores (SMD = −1.19, 95% CI: −1.42 to −0.95, p < 0.00001). Eleven studies indicated that TEAS decreased the incidence of PONV (RR = 0.47.95% CI:0.37~0.61, P<0.00001). Four studies were included in the meta-analysis of postoperative nausea, showing a significant reduction in incidence in the TEAS group compared to controls (RR = 0.33, 95% CI: 0.22 to 0.49, p < 0.00001). Another four studies showed a downward trend in postoperative vomiting but without statistical significance (RR = 0.69, 95% CI: 0.44 to 1.09, p = 0.11).

TEAS appears to be an effective adjunctive intervention for alleviating postoperative pain and nausea in patients undergoing cancer surgery, showing clear clinical advantages. Further high-quality, large-scale, and multicenter studies are warranted to confirm its long-term efficacy and to promote the standardization of TEAS protocols for broader clinical application.

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251038890

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** LIPN (lipase family member N) [NCBI Gene 643418] {aka ARCI8, LI4, LIPL4, bA186O14.3}, PCSK5 (proprotein convertase subtilisin/kexin type 5) [NCBI Gene 5125] {aka PC5, PC6, PC6A, SPC6}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}
- **Diseases:** Nausea (MESH:D009325), Gastric cancer (MESH:D013274), respiratory depression (MESH:D012131), TEAS (MESH:D004556), vomiting (MESH:D014839), itching (MESH:D011537), inflammation (MESH:D007249), headaches (MESH:D006261), trauma (MESH:D014947), skin reactions (MESH:D012871), cervical cancer (MESH:D002583), Pain (MESH:D010146), sleep disturbances (MESH:D012893), Cancer (MESH:D009369), Postoperative Pain (MESH:D010149), lung cancer (MESH:D008175), irritation (MESH:D001523), anxiety (MESH:D001007), neuroinflammatory (MESH:D000090862), depression (MESH:D003866), breast cancer (MESH:D001943), POV (MESH:D020250), constipation (MESH:D003248), impaired liver and kidney function (MESH:D056486), gastrointestinal tumors (MESH:D005770), erythema (MESH:D004890), QT prolongation (MESH:D008133), anemia (MESH:D000740), Colorectal cancer (MESH:D015179), malnutrition (MESH:D044342), thyroid cancer (MESH:D013964), postoperative complication (MESH:D011183), excessive gastrointestinal motility (MESH:D005767)
- **Chemicals:** fentanyl (MESH:D005283), morphine (MESH:D009020), ondansetron (MESH:D017294), 5-HT (MESH:D012701), CV17 (-)
- **Species:** Meleagris gallopavo (common turkey, species) [taxon 9103], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946081/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946081/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946081/full.md

---
Source: https://tomesphere.com/paper/PMC12946081